Hypertension Associated with Inhibition of the VEGF Pathway in Oncology Patients - Takeaways - MDSpire

Hypertension Associated with Inhibition of the VEGF Pathway in Oncology Patients

  • By

  • Nicolas L. Palaskas

  • Jung Hyun Kim

  • Silvia Fernanda López Moreno

  • Bernardo Casso-Chapa

  • Noah I. Beinart

  • Nnenne Nnanna

  • Keila Carolina Ostos Mendoza

  • Anita Deswal

  • Syed Wamique Yusuf

  • Efstratios Koutroumpakis

  • Jun-ichi Abe

  • Michael S. Ewer

  • April 28, 2026

  • 0 min

Share

  • 1

    VEGF pathway inhibitors are a significant cause of therapy-induced hypertension in oncology patients, necessitating careful monitoring and management.

  • 2

    Hypertension related to VEGF inhibition serves as both a cardiovascular risk factor and a potential biomarker for therapeutic efficacy in cancer treatments.

  • 3

    Early detection and aggressive blood pressure control are crucial for improving cardiovascular and oncologic outcomes in patients receiving VEGF inhibitors.

  • 4

    Renin-angiotensin system inhibitors and calcium-channel blockers are recommended as first-line treatments for managing therapy-induced hypertension.

  • 5

    A multidisciplinary approach involving oncology, cardiology, and primary care is essential for effective management of hypertension in cancer patients.

Original Source(s)

Hypertension Associated with Inhibition of the VEGF Pathway in Oncology Patients

  • by Nicolas L. Palaskas, Jung Hyun Kim, Silvia Fernanda López Moreno, Bernardo Casso-Chapa, Noah I. Beinart, Nnenne Nnanna, Keila Carolina Ostos Mendoza, Anita Deswal, Syed Wamique Yusuf, Efstratios Koutroumpakis, Jun-ichi Abe, Michael S. Ewer

  • April 28, 2026

Related Content

What RevMed’s pancreatic cancer drug meant for one patient

Ultrasound-driven mechanical immunomodulation enhances tumor treatment sensitivity: advances from tumor mechanical immunobiology to immunotherapy applications

Direct comparison of efficacy of combining ivermectin versus five first-line chemotherapy drugs with recombinant methioninase against colon-cancer cells